Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mauna Kea Technologies obtains FDA clearance for Cellvizio in urology


Wednesday, 5 Mar 2014 12:26pm EST 

Mauna Kea Technologies SA:Obtains 510(k) regulatory clearance from the U.S. Food & Drug Administration (FDA) for Cellvizio in the field of urology.Clearance covers the use of Cellvizio's Uroflex B and CystoFlex F Confocal Miniprobes within anatomical tracts including but not limited to urethra, bladder, and ureter, accessed through an endoscope or endoscopic accessories.